The Desmoid Tumor Research Foundation is dedicated to spreading knowledge about desmoid tumors among clinicians and researchers.
We form partnerships with entities that specialize in creating authorized Continuing Medical Education (CME) credit courses for medical professionals, providing the opportunity and incentive to increase their understanding of this rare tumor type and its treatment.
These courses are available to medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors to ensure the greatest potential impact on patient outcomes.
The following CME-certified programs on desmoid tumors are available
Creators:
PeerView & the DTRF (Made possible with support from SpringWorks Therapeutics)
Availability:
Now through November 26, 2024
Mediums:
The PeerView inQuiry presentation can be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.
Description:
Until recently, ICD-10-CM codes for desmoid tumors (DTs) were broadly defined, creating a significant impediment to research efforts. Through a didactic expert-led discussion, get to know the new ICD-10-CM codes for desmoid tumors and learn how to navigate these codes more efficiently as a healthcare provider or researcher in this new question-based activity that lets you earn your CME credit as you go.
This educational program leverages microlearning through question-based segments to help clinicians better navigate the variable presentations of desmoid tumors and the new ICD-10-CM codes. Throughout the program, two leading experts address gaps and barriers that affect healthcare providers, patients, and researchers by offering practical guidance on current evidence-based diagnostic strategies, describing the new desmoid tumor–specific ICD-10-CM codes, and detailing the new codes’ implications for clinical practice, patient care, and research. In addition to these question-based segments, downloadable Practice Aids and additional resources for clinicians and patients are available.
Upon completion of this activity, participants should be better able to:
- Discuss the gaps and barriers in the diagnosis and treatment of desmoid tumors (DTs), including the prior lack of DT-specific ICD-10-CM codes
- Characterize the details of the new DT-specific ICD-10-CM codes, including the subcategories for tumor locations
- Implement best practices for integrating the new DT-specific ICD-10-CM codes in clinical and research settings
- Employ the latest recommendations for establishing an accurate diagnosis and assigning the correct ICD-10-CM codes to patients with DTs to guide further care decisions
Creators:
PeerView & the DTRF (Made possible with support from SpringWorks Therapeutics)
Availability:
Now through December 29, 2023
Mediums:
The PeerView onDemand presentation can be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.
Description:
The treatment and management for desmoid tumors is currently transitioning from surgical approaches to more conservative strategies by utilizing systemic therapies. Systemic therapies travel through blood to cells all over the body, to the whole “system.” The discovery that desmoid tumors are universally associated with genetic alterations in the Wnt/β-catenin pathway led to the development of gamma secretase inhibitors (GSIs). GSIs are a new promising class of therapies, and several are in late-phase testing.
This PeerView educational activity, was based on a the CTOS 2022 Live Hybrid Symposium held on November 29, 2022 with the replay immediately following. This on-demand activity is available for CME credit through December 29, 2023 and features a panel of leading experts in managing patients with desmoid tumors. They provide expert insights and practical guidance for navigating the latest treatment advances, including GSIs for desmoid tumors. In addition, they discuss illustrative cases and clinical scenarios to demonstrate the emerging role and integration of novel GSIs in real-world patient care settings.
This learner interactive PeerView program is chaired and presented by Bernd Kasper, MD, PhD from the Mannheim Cancer Center (MCC) in Mannheim, Germany. Dr. Kasper is joined on the faculty by Mrinal Gounder, MD from the Memorial Sloan Kettering Cancer Center in New York, New York and Alessandro Gronchi, MD from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.
Upon completion of this activity, participants should be better able to:
- Describe the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of adult and pediatric desmoid tumors
- Implement validated strategies that harness multidisciplinary team-based approaches to diagnose desmoid tumors, including referring patients to sarcoma specialists
- Integrate novel therapeutic approaches based on current evidence to include emerging therapies in the context of clinical trial enrollment into the treatment plans of patients with desmoid tumors
Creators:
PeerView Institute for Medical Education (PVI) & the Desmoid Tumor Research Foundation (DTRF) (Made Possible with support from SpringWorks Therapeutics)
Availability:
Now through February 22, 2024.
Description:
Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors.
This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions.
This PeerView program is chaired and presented by Ravin Ratan, MD, M.Ed from the MD Anderson Cancer Center. Dr. Ratan is joined on the faculty by Christina L. Roland, MD, MS, FACS, from MD Anderson Cancer Center and desmoid tumor patient, Kathleen Hodgkins.
Upon completion of this activity, participants should be better able to:
- Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors
- Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors
- Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences
Table of Contents
Continue Exploring
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.
The Annual DTRF International Desmoid Tumor Research Workshop
DTRF Patient Meeting
Our Patient Meeting is a time to hear from clinicians, researchers, and desmoid patients and caregivers during our annual DTRF Together We Will Weekend.
